Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fen Li
- Target Recruit Count
- 30
- Registration Number
- NCT05666336
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
The Clinical Features and Pregnancy Outcomes of RA Patients
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 100
- Registration Number
- NCT05651373
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05645718
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 80
- Registration Number
- NCT05644210
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT05627557
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 300
- Registration Number
- NCT05605899
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 24
- Registration Number
- NCT05600686
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-10-05
- Target Recruit Count
- 60
- Registration Number
- NCT05594784
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 900
- Registration Number
- NCT05578976
- Locations
- 🇺🇸
Orlando Health Cancer Institute /ID# 232626, Orlando, Florida, United States
🇺🇸University of Illinois at Chicago /ID# 226889, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore /ID# 225421, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.